Dublin, Ireland, June 9, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced new data on IBL-202, a dual mechanism PIM/PI3 kinase inhibitor and IBL-301, a PIM/PI3K/mTOR inhibitor, will be highlighted in a e-poster presentation at the 20th Congress of the European Hematology Association (EHA) being held June 11 – 14, 2015, at the Reed Messe Wien Exhibition & Congress Center in Vienna, Austria.
The pre-clinical data was generated through a collaboration between Inflection Biosciences and the National University of Ireland, Galway, led by Professor Michael O’Dwyer and funded by the Health Research Board.
The details for the poster presentation are as follows:
Date & Time: Friday, June 12, 5 pm -7 pm CEST
Poster Title: Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR inhibitors in multiple myeloma
Presenter: Dr. Mairead Reidy, National University of Ireland, Galway
Abstract Number: E1237
Session Title: Myeloma and other monoclonal gammopathies - Biology
Location: E-Poster Screens
The full abstract can be viewed here.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com